The Japan-China Biopharma Gap
Structural Barriers, Strategic Risks, and the Path to Partnership

Japan is the world’s second-largest pharmaceutical market. China is one of the most active sources of biopharma innovation. Yet licensing activity between the two remains surprisingly limited. Not because the opportunity is absent, but because the pathway to capture it remains underbuilt. In conversations with more than 50 Chinese biotech executives, every single one expressed interest in partnering with Japanese companies. Very few had a strategy  or capability to make it happen.

1. The gap is not scientific. It is operational readiness. The assets, therapeutic overlap, and commercial logic exist. What is missing is the operating model. Japanese pharma faces long governance timelines of 6–12+ months and limited China-facing BD infrastructure, while Chinese biotechs often lack Japan-ready materials, regulatory strategies, and local relationships. Interest is not translating into execution.
2. Western competitors are not waiting. Every transaction a US or European company completes today narrows the available asset pool and raises the cost of late entry. The window remains open, but it is narrowing.
3. The corridor is workable. It needs a playbook. Eisai, Santen, and Takeda have shown that Japan-China partnerships can happen when the right structures are in place. Our white paper lays out a practical roadmap for both sides, from governance redesign and China-facing infrastructure to Japan-rights carveouts and early PMDA planning.

We welcome the opportunity to discuss further.